Insurance Co Name

Insurance Co Address

June 27, 2023

Re: Name: Patient Name

DOB: Enter date of birth

Account #: Enter insurance company account number

To whom it may concern:

This letter is to support an appeal for choose a reason H.P. Acthar for my patient enter patient name. Enter patient name is experiencing a severe exacerbation of multiple sclerosis with acute neurological deficits choose a rationale.

Enter patient name suffered an acute exacerbation of multiple sclerosis on enter date, with symptoms including enter symptoms. Enter patient name has contraindications to using high-dose corticosteroids for the management of these symptoms. Enter reasons for not using steroids, or that oral and IV steroids have already been tried and dates of treatment.

Controlled clinical trials have shown Acthar Gel to be effective in speeding the resolution of acute exacerbations of multiple sclerosis, as such, it has FDA approval to treat MS exacerbations. A recent literature review confirmed the efficacy of H.P. Acthar for MS exacerbation treatment and found it to be associated with lower post-therapy healthcare utilization and medical costs, including decreases in hospitalizations, hospital length of stay, outpatient visits, and emergency department visits.1

A prospective open label registry study recently evaluated 125 patients treated with Acthar, who were followed for 2 years. 60% of patients in the study had a lack of response or intolerance to traditional steroids. The study showed that patients had an improvement in their EDSS scores, as well as a decrease in the use of ED visits and outpatient, specialist visits. This study showed patients had significant improvements in MS assessment scores after treatment with Acthar, and supports the efficacy and tolerability of Acthar for MS relapse.2

H.P Acthar is medically necessary for my patient, enter patient name, as enter patient name choose a rationale . I respectfully request that you choose consider/reconsider coverage for this patient. Thank you in advance for your timely response.

Sincerely,

Click or tap here to enter text.

Click or tap here to enter text.

Click or tap here to enter text.

1 Philbin M, Niewoehner J, Wan GJ. (2017). Clinical and Economic Evaluation of Repository Corticotropin Injection: A Narrative Literature Review of Treatment Efficacy and Healthcare Resource Utilization for Seven Key Indications. Adv Ther, 34(8), 1775-1790. doi: 10.1007/s12325-017-0569-9.

2 Kaplan J, Miller T, Baker M, Due B, Zhao E. A Prospective Observational Registry of Repository Corticotropin Injection (Acthar® Gel) for the Treatment of Multiple Sclerosis Relapse. Front Neurol. 2020 Dec 22;11:598496. doi: 10.3389/fneur.2020.598496. PMID: 33414758; PMCID: PMC7783159.